Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 2086 AL 2100

Association between apolipoprotein E genotypes and Parkinson's disease

Pulkes T, Papsing C, Mahasirimongkol S, Busabaratana M, Kulkantrakorn K, Tiamkao S.

J Clin Neurosci. 2011 Oct;18(10):1333-5. doi: 10.1016/j.jocn.2011.01.028. Epub 2011 Jul 22.

Acute versus long-term effects of 6-hydroxydopamine on oxidative stress and dopamine depletion in the striatum of mice

Varcin M, Bentea E, Mertens B, Haute CV, Baekelandt V, Michotte Y, Sarre S.

J Neurosci Methods. 2011 Nov 15;202(2):128-36. doi: 10.1016/j.jneumeth.2011.07.004. Epub 2011 Jul 18.

Genetic mutations and functions of PINK1

Kawajiri S, Saiki S, Sato S, Hattori N.

Trends Pharmacol Sci. 2011 Oct;32(10):573-80. doi: 10.1016/j.tips.2011.06.001. Epub 2011 Jul 23.

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

Huot P, Fox SH, Newman-Tancredi A, Brotchie JM.

J Pharmacol Exp Ther. 2011 Oct;339(1):2-8. doi: 10.1124/jpet.111.184093. Epub 2011 Jul 22.

An unusual cause of dementia: essential diagnostic elements of corticobasal degeneration-a case report and review of the literature

Mastrolilli F, Benvenga A, Di Biase L, Giambattistelli F, Trotta L, Salomone G, Quintiliani L, Landi D, Melgari JM, Vernieri F.

Int J Alzheimers Dis. 2011;2011:536141. doi: 10.4061/2011/536141. Epub 2011 Jul 12.

Comment: should we diagnose MCI in Parkinson disease?

Korczyn AD.

J Neural Transm (Vienna). 2011 Aug;118(8):1177. doi: 10.1007/s00702-011-0687-5.

Open-label surgical trials for Parkinson disease: time for reconsideration

Alterman RL, Tagliati M, Olanow CW.

Ann Neurol. 2011 Jul;70(1):5-8. doi: 10.1002/ana.22453.

A BACwards glance at neurodegeneration: molecular insights into disease from LRRK2, SNCA and MAPT BAC-transgenic mice

Johnson SJ, Wade-Martins R.

Biochem Soc Trans. 2011 Aug;39(4):862-7. doi: 10.1042/BST0390862.

Modelling early responses to neurodegenerative mutations in mice

Gilley J, Adalbert R, Coleman MP.

Biochem Soc Trans. 2011 Aug;39(4):933-8. doi: 10.1042/BST0390933.

Hepatic response to aluminum toxicity: dyslipidemia and liver diseases

Mailloux RJ, Lemire J, Appanna VD.

Exp Cell Res. 2011 Oct 1;317(16):2231-8. doi: 10.1016/j.yexcr.2011.07.009. Epub 2011 Jul 20.

Slowly progressive Parkinson syndrome due to thalamic butterfly astrocytoma

Wächter T, Engeholm M, Bisdas S, Schittenhelm J, Gasser T, Krüger R.

Neurology. 2011 Jul 26;77(4):404-5. doi: 10.1212/WNL.0b013e3182267bc4.

[The presymptomatic stage of neurodegenerative disorders]

Klein C, Hagenah J, Landwehrmeyer B, Münte T, Klockgether T.

Nervenarzt. 2011 Aug;82(8):994-1001. doi: 10.1007/s00115-011-3258-y.

Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease

Sanford M, Scott LJ.

CNS Drugs. 2011 Aug;25(8):699-719. doi: 10.2165/11206750-000000000-00000.

Effects of estrogens and endocrine-disrupting chemicals on cell differentiation-survival-proliferation in brain: contributions of neuronal cell lines

Habauzit D, Flouriot G, Pakdel F, Saligaut C.

J Toxicol Environ Health B Crit Rev. 2011;14(5-7):300-27. doi: 10.1080/10937404.2011.578554.

Neurotoxicity of endocrine disruptors: possible involvement in brain development and neurodegeneration

Masuo Y, Ishido M.

J Toxicol Environ Health B Crit Rev. 2011;14(5-7):346-69. doi: 10.1080/10937404.2011.578557.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias